5 Lidocaine medicated plaster in elderly patients with postherpetic neuralgia: Results of a compassionate use programme in france

Drugs and Aging

Volumn 28, Issue 9, 2011, Pages 693-702

  Clère, Florentin ^a   Delorme Morin, Claire ^a   George, Brigitte ^b   Navez, Malou ^c   Rioult, Bruno ^d   Tiberghien Chatelain, Florence ^e   Ganry, Hervé ^f  

^a CENTRE HOSPITALIER   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c HÔPITAL NORD   (France)

^d Centre Catherine de Sienne   (France)

^e UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^f GRÜNENTHAL GMBH   (Germany)

Author keywords

Analgesics; Elderly; Lidocaine; Postherpetic neuralgia; Topical

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; CARBAMAZEPINE; GABAPENTIN; LIDOCAINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; PREGABALIN; SEROTONIN UPTAKE INHIBITOR; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT;

AGED; APPLICATION SITE BURNING; APPLICATION SITE DERMATITIS; APPLICATION SITE ERYTHEMA; APPLICATION SITE PRURITUS; APPLICATION SITE RASH; APPLICATION SITE URTICARIA; ARTICLE; CLINICAL PRACTICE; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; ELDERLY CARE; FEMALE; FOLLOW UP; FRANCE; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PETECHIA; PLASTER CAST; POSTHERPETIC NEURALGIA; PRESCRIPTION; PRIORITY JOURNAL; SKIN DISEASE; SKIN MANIFESTATION; SKIN PAIN; SYNCOPE; TRANSCUTANEOUS NERVE STIMULATION; TREATMENT DURATION;

AGED; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; CALCIUM SULFATE; COMPASSIONATE USE TRIALS; FEMALE; FRANCE; HUMANS; LIDOCAINE; MALE; NEURALGIA, POSTHERPETIC; TREATMENT FAILURE;

EID: 80052822962     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11595600-000000000-00000     Document Type: Article

References (32)

1. Bouhassira D, Lantéri-Minet M, Attal N, et al. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 2008; 136 (3): 380-7 (Pubitemid 351680253)
2. Johnson RW, Wasner G, Saddier P, et al. Herpes zoster and postherpetic neuralgia: optimizing management in the elderly patient. Drugs Aging 2008; 25 (12): 991-1006
3. Dworkin RH, Gnann Jr JW, Oaklander AL, et al. Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia. J Pain 2008 Jan; 9 Suppl.1: S37-44
4. Johnson RW, McElhaney J. Postherpetic neuralgia in the elderly. Int J Clin Pract 2009 Sep; 63 (9): 1386-91
5. Sadosky A, McDermott AM, Brandenburg NA, et al. A review of the epidemiology of painful diabetic neuropathy, postherpetic neuralgia, and less commonly studied neuropathic pain conditions. Pain Practice 2008 Mar; 8 (1): 45-56
6. Dworkin RH, Malone DC, Panarites CJ, et al. Impact of postherpetic neuralgia and painful diabetic peripheral neuropathy on health care costs. J Pain 2010 Apr; 11 (4): 360-8
7. Gauthier A, Breuer J, Carrington D, et al. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect 2009 Jan; 137 (1): 38-47
8. Yawn BP, Saddier P, Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007 Nov; 82 (11): 1341-9 (Pubitemid 350060129)
9. Johnson RW, Bouhassira D, Kassianos G, et al. The impact of herpes zoster and post-herpetic neuralgia on quality-oflife. BMC Med 2010 Jun 21; 8 (1): 37
10. Oster G, Harding G, Dukes E, et al. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain 2005 Jun; 6 (6): 356-63 (Pubitemid 40804340)
11. Baron R, Binder A,Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol 2010 Aug; 9: 807-19
12. Baron R, Tölle TR, Gockel U, et al. A cross-sectional cohort survey in 2100 patients with painful neuropathy and postherpetic neuralgia: differences in demographic data and sensory symptoms. Pain 2009 Nov; 146 (1-2): 34-40
13. Finnerup NB, Otto M, Jensen TS, et al. An evidence-based algorithm for the treatment of neuropathic pain. Med- GenMed 2007 May 15; 9 (2): 36
14. Dworkin RH, OConnor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010 Mar; 85 (3 Suppl.): S3-14
15. Rowbotham MC, Davies PS, Verkempinck C, et al. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain 1996 Apr; 65 (1): 39-44 (Pubitemid 26227686)
16. Galer BS, Rowbotham MC, Perander J, et al. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain 1999 Apr; 80 (3): 533-8 (Pubitemid 29182702)
17. Baron R, Mayoral V, Leijon G, et al. 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. Curr Med Res Opin 2009 Jul; 25 (7): 1663-76
18. Binder A, Bruxelle J, Rogers P, et al. Topical 5% lidocaine (lignocaine) medicated plaster treatment for post-herpetic neuralgia: results of a double-blind, placebo-controlled, multinational efficacy and safety trial. Clin Drug Investig 2009; 29 (6): 393-408
19. Rehm S, Binder A, Baron R. Post-herpetic neuralgia - 5% lidocaine medicated plaster, pregabalin, or a combination of both? A randomized, open, clinical effectiveness study. Curr Med Res Opin 2010 Jul; 26 (7): 1607-19
20. Galer BS, Gammaitoni AR. More than 7 years of consistent neuropathic pain relief in geriatric patients. Arch Intern Med 2003 Mar 10; 163 (5): 628 (Pubitemid 36314352)
21. Hans G, Sabatowski R, Binder A, et al. Efficacy and tolerability of a 5% lidocaine medicated plaster for the topical treatment of post-herpetic neuralgia: results of a long-term study. Curr Med Res Opin 2009 May; 25 (5): 1295-305
22. Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS). Notice to applicants for Temporary Authorisation for Use (ATU) [in French]. 2007Nov [online]. Available from URL: http://www.afssaps.fr/Activites/Au torisations-temporaires-d-utilisation [Accessed 2011 Jun 1]
23. World Health Organisation. Cancer pain ladder [online]. Available from URL: http://www.who.int/cancer/pallia tive/painladder/en/ [Accessed 2010 Jul 15]
24. International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). Medical dictionary for regulatory activities (MedDRA). Version 11. Chantilly (VA): MedDRA MSSO, 2008
25. Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010; 17 (9): 1113-e88
26. Douglas MW, Johnson RW, Cunningham AL. Tolerability of treatments for postherpetic neuralgia. Drug Saf 2004; 27: 1217-33 (Pubitemid 40066083)
27. Zin CS, Nissen LM, Smith MT. An update on the pharmacological management of post-herpetic neuralgia and painful diabetic neuropathy. CNS Drugs 2008; 22 (5): 714-42
28. McKeage K, Keam SJ. Pregabalin: in the treatment of postherpetic neuralgia. Drugs Aging 2009; 26 (10): 883-92
29. Gammaitoni AR, Alvarez NA, Galer BS. Safety and tolerability of the lidocaine patch 5%, a targeted peripheral analgesic: a review of the literature. J Clin Pharmacol 2003 Feb; 43 (2): 111-7 (Pubitemid 36125935)
30. Chidiac C, Bruxelle J, Daures J-P, et al. Characteristics of patients with herpes zoster on presentation to practitioners in France. Clin Infect Dis 2001 July; 33: 62-9 (Pubitemid 32554504)
31. Van Seventer R, Sadosky A, Lucero M, et al. A crosssectional survey of heath state impairment and treatment patterns in patients with postherpetic neuralgia. Age Ageing 2006; 35: 132-7
32. Burt CW, Woodwell D. Tests of methods to improve response to physician surveys [online]. Available from URL: http://www.fcsm.gov/05papers/Burt- Woodwell-VIIB.pdf [Accessed 2011 Mar 1]